Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SCRI-CARB7H3(s)x19 |
| Synonyms | |
| Therapy Description |
SCRI-CARB7H3(s)x19 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and CD19, truncated EGFR (EGFRt), and undisclosed costimulatory domains, which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) and CD19 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SCRI-CARB7H3(s)x19 | CD19 Immune Cell Therapy 74 CD276 Immune Cell Therapy 12 | SCRI-CARB7H3(s)x19 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and CD19, truncated EGFR (EGFRt), and undisclosed costimulatory domains, which potentially induce toxicity in tumor cells expressing CD276 (B7-H3) and CD19 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|